Systems and methods for delivery of a therapeutic agent
Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.
1. A method of treating a nasal condition of a patient comprising:
positioning a distal portion of a treatment device proximate to target tissue in a nasopharyngeal passage of a patient; and
administering therapy to the target tissue with the treatment device so as to disrupt neural activity such that mucus secretion is reduced in the nasopharyngeal passage;
wherein administering therapy comprises at least one of delivering energy to the target tissue and changing the temperature of the target tissue.
2. The method of claim 1 , wherein administering therapy comprises delivering energy from at least one energy delivery element on the treatment device.
3. The method of claim 2 , wherein the energy comprises RF energy.
4. The method of claim 2 , wherein the energy comprises ultrasound energy.
5. The method of claim 2 , wherein the energy comprises microwave energy.
6. The method of claim 2 , wherein the energy comprises AC or DC current.
7. The method of claim 1 , wherein changing the temperature comprises transferring thermal energy between the treatment device and the target tissue.
8. The method of claim 1 , wherein the energy is delivered or the temperature is changed so as to electroporate cells in the target tissue.
9. The method of claim 1 , wherein administering therapy comprises contacting target tissue with a delivery portion of the treatment device.
10. The method of claim 9 , wherein the target tissue is contacted without penetrating the target tissue.
11. The method of claim 9 , wherein the target tissue is penetrated by the treatment delivery portion of the treatment device.
12. The method of claim 1 , wherein administering therapy further comprises delivering an agent to the target tissue.
13. The method of claim 12 , wherein the agent comprises a neurotoxin.
14. The method of claim 1 , wherein administering therapy disables adrenergic cells in the target tissue.
15. The method of claim 1 , wherein administering therapy blocks or disrupts acetycholine release in cells in the target tissue.
16. The method of claim 15 , wherein the cells comprise goblet cells or epithelial cells.
17. A method of treating a nasal condition of a patient comprising:
positioning a distal portion of a treatment device proximate to target tissue in a nasopharyngeal passage of a patient; and
administering therapy to the target tissue with the treatment device to alter nasopharyngeal cells such that congestion in the nasopharyngeal passage is reduced;
wherein administering therapy comprises delivering energy to the target tissue.
18. The method of claim 17 , wherein the energy is delivered from an energy delivery element on the treatment device.
19. The method of claim 18 , wherein the energy comprises RF energy.
20. The method of claim 19 , wherein the energy delivery element comprises a monopolar or bipolar electrode.
21. The method of claim 18 , wherein the energy delivery element comprises a plurality of electrodes.
22. The method of claim 18 , wherein the energy delivery element is configured to concentrate energy laterally relative to the distal portion of the treatment device.
23. The method of claim 22 , wherein the energy delivery element comprises at least one electrode disposed on a lateral side of the distal portion of the treatment device.
24. The method of claim 18 , further comprising a monitoring electrode or system on the treatment device.
25. The method of claim 24 , wherein the monitoring electrode or system comprises a thermocouple, ultrasound transducer, fiberoptic, or sensing or stimulating electrode.
26. The method of claim 17 , wherein the energy is delivered so as to disable adrenergic cells.
27. The method of claim 26 , wherein the adrenergic cells are disabled such that mucus production in the nasopharyngeal passage is reduced.
28. The method of claim 26 , wherein the energy is delivered to as to electroporate the adrenergic cells.
29. The method of claim 28 , further comprising delivering an agent to disable the adrenergic cells.
30. The method of claim 29 , wherein the agent comprises a neurotoxin.